From 1 July 2026, a new requirement issued by ECHA comes into effect: for all renewal applications for the approval of biocidal active substances, the dossier data must be submitted mandatorily in IUCLID format. What is changing? ECHA has stipulated that, for renewal applications submitted from 1 July 2026 onwards, the following data must be available in IUCLID format: All documentation from the original application for approval of the biocidal active substance All relevant approval data in accordance with the Biocidal Products Regulation (BPR) The data must be created or updated using the current version of IUCLID Applications that do not comply with the new format requirements risk delays or rejection of the renewal procedure. What does this mean for you? If your company is planning a renewal of the active substance approval, or has already submitted an application, you must ensure that your existing dossier: Has been updated to the latest version of IUCLID Contains all relevant data completely and correctly in IUCLID format Meets the formal requirements of the BPR We are here to support you – efficiently and competently Our Regulatory Affairs team has many years of experience in the preparation and updating of IUCLID dossiers for biocidal active substances. We are happy to assist you with migrating your dossier to the current version of IUCLID. Get in touch today Contact us today for a non-binding consultation – here: Contact Dr. Brill Regulatory Services – Your Trusted Partner for Biocidal Products Regulatory Compliance

The Hydrotox Labor für Ökotoxikologie und Gewässerschutz GmbH team was represented with a booth at the annual meeting of SETAC Europe (Society of Environmental Toxicology and Chemistry) in Maastricht, the Netherlands, from May 17-21, 2026, together with colleagues from Dr. Brill Regulatory GmbH. Among the more than 2,500 participants from more than 60 countries, we were able to meet many of our long-standing customers and colleagues, but also make many new contacts. The scientific program was again very comprehensive with several thousand posters and up to ten parallel sessions and included topics such as persistence assessment, animal-free replacement methods, endocrine effects and regulatory issues, which were particularly interesting for us. Elena Perabo gave a presentation on our project on the sponge city, which is about to be completed, entitled "Sustainable green roofs for the implementation of the sponge city: Determination of ecotoxicologically safe construction products for green roofs", which met with great interest. Andrea Brunswik-Titze, together with Ulrich Jöhncke and colleagues from the Federal Environment Agency, presented a poster with the titel "Round Robin Test: consolidation of OECD ready biodegradability tests", which was also presented in a Poster Corner. It illustrated the actual status of our project to organize that round robin test. Furthermore, Andrea Brunswik-Titze, Jessica Bühler and Marie Canon presented a poster on methodological approaches in the testing of the biodegradability of polymers entitled "Biodegradability of polymers in aquatic test systems: ISO 14852 - feasibility study for different concentrations of test item and inoculum". In a third poster, first results of the project on the assessment of endocrine effects induced by construction products were presented with the title "Assessment of endocrine effects of construction products in the environment" by Elena Perabo and Martina Springmann together with Peter Behnisch from BioDetection Systems in Amsterdam. And in a fourth poster, Heike Schimmelpfennig, Andrea Brunswik-Titze, and Elena Perabo presented a comparison of exposure models used to simulate the entry of substances into various environmental compartments within the risk assessments under the legal frameworks of biocides, plant protection products, and chemicals under REACH, titled "Comparison of exposure modelling tools used in different regulatory areas." We are very happy about the successful participation in this conference and look forward to next year, when the conference will take place in Geneva. If you are interested in learning more about any of the topics presented in Maastricht or about the other services offered by our institutes, we would be happy to assist you! Contact: HERE   The SETAC Europe Annual Meeting is an annual conference of the Society of Environmental Toxicology and Chemistry (SETAC) Europe that brings together scientists, policy makers and industry representatives to discuss current issues in the fields of environmental toxicology, ecotoxicology and environmental chemistry. Main features of the conference: Topics: Environmental risk research, life cycle assessment, regulatory developments and scientific policy advice Formats: Scientific sessions, plenary lectures, training sessions and networking events Participants: 2,000-2,500 experts from over 60 countries The conference serves as a platform for the exchange of new findings and promotes cooperation between research, industry and authorities. Link: SETAC Europe 36th Annual Meeting

The revised Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00 Rev. 1 – Corr.) came into force in September 2024. For pharmaceutical companies, it introduces additional requirements for Environmental Risk Assessments (ERA). We can support you in meeting these expectations – efficiently, scientifically robust, and fully aligned with the latest regulatory standards.   Our Services for Pharmaceutical Companies Systematic literature review in accordance with the current ERA guideline Gap analysis: identification of missing studies and data gaps Evaluation and conduct of Phase I/II ERAs Support in responding to authority queries Why choose Dr. Brill Regulatory Services? With more than 20 years of experience in environmental risk assessment, Heike Schimmelpfennig brings extensive expertise from industry, regulatory authorities, and international regulatory frameworks – including over 10 years at ECHA and collaborations with EMA. You will benefit from a unique combination of regulatory know how, scientific expertise, and hands on dossier experience.   Want to Ensure Full ERA Compliance? We support you from initial screening to developing complete assessment documents – compliant, efficient, and strategically sound.   Contact us for a non binding consultation - here: Contact.   Dr. Brill Regulatory Services – Your Partner for Regulatory Excellence in the Pharmaceutical Sector